Skip to main content
. 2019 Apr 13;85(8):1781–1789. doi: 10.1111/bcp.13965

Figure 4.

Figure 4

Vascular endothelial growth factor (VEGF)‐A changes predicts benefit from cediranib: survival curves. Progression‐free survival (PFS) of patients with or without elevated VEGF‐A were plotted based on multivariate Cox proportional hazard model. In the placebo arm, patients with elevated VEGF‐A have reduced PFS than those without, whereas in the cediranib arm patients with elevated VEGF‐A demonstrate improved PFS